Constellation Pharmaceuticals Inc (NASDAQ:CNST) Given Consensus Rating of “Buy” by Brokerages

Share on StockTwits

Constellation Pharmaceuticals Inc (NASDAQ:CNST) has received a consensus rating of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $41.67.

A number of equities analysts have recently commented on CNST shares. Oppenheimer raised their price objective on shares of Constellation Pharmaceuticals from $18.00 to $40.00 in a report on Wednesday, November 6th. HC Wainwright raised their price objective on shares of Constellation Pharmaceuticals from $18.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $40.00 price objective (up from $17.00) on shares of Constellation Pharmaceuticals in a report on Thursday, November 7th. ValuEngine downgraded shares of Constellation Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 15th. Finally, Royal Bank of Canada raised their price objective on shares of Constellation Pharmaceuticals to $42.00 and gave the stock a “positive” rating in a report on Thursday, November 7th.

NASDAQ:CNST opened at $38.48 on Monday. Constellation Pharmaceuticals has a 1 year low of $4.01 and a 1 year high of $45.42. The firm’s fifty day simple moving average is $14.82 and its 200 day simple moving average is $10.72. The company has a current ratio of 5.19, a quick ratio of 5.19 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $1.27 billion, a PE ratio of -7.70 and a beta of 5.32.

Constellation Pharmaceuticals (NASDAQ:CNST) last posted its earnings results on Wednesday, November 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. As a group, analysts anticipate that Constellation Pharmaceuticals will post -2.99 EPS for the current fiscal year.

In other news, Director Anthony B. Evnin purchased 2,823,529 shares of the business’s stock in a transaction that occurred on Thursday, October 3rd. The stock was purchased at an average cost of $8.50 per share, with a total value of $23,999,996.50. Also, major shareholder Group L. P. Column purchased 1,411,764 shares of the business’s stock in a transaction that occurred on Thursday, October 3rd. The shares were purchased at an average cost of $8.50 per share, with a total value of $11,999,994.00. Insiders have sold a total of 317,971 shares of company stock valued at $10,976,079 over the last three months. 43.70% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in CNST. P.A.W. Capital Corp bought a new position in Constellation Pharmaceuticals during the 2nd quarter valued at about $1,474,000. Wells Fargo & Company MN increased its position in Constellation Pharmaceuticals by 42.1% in the 2nd quarter. Wells Fargo & Company MN now owns 13,937 shares of the company’s stock valued at $171,000 after acquiring an additional 4,132 shares in the last quarter. Alps Advisors Inc. acquired a new stake in Constellation Pharmaceuticals in the 2nd quarter valued at about $663,000. Acadian Asset Management LLC acquired a new stake in Constellation Pharmaceuticals in the 2nd quarter valued at about $61,000. Finally, Northern Trust Corp increased its position in Constellation Pharmaceuticals by 12.7% in the 2nd quarter. Northern Trust Corp now owns 146,358 shares of the company’s stock valued at $1,797,000 after acquiring an additional 16,548 shares in the last quarter. 65.85% of the stock is owned by hedge funds and other institutional investors.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Recommended Story: Treasury Bonds

Analyst Recommendations for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.